Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.02.2013 | review

The pathology of low and intermediate neuroendocrine lung tumors

verfasst von: Helmut H Popper, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Neuroendocrine lung tumors can be grouped into four epithelial and one mesenchymal tumor. The epithelial neuroendocrine tumors are further divided into two high-grade carcinomas, large and small cell neuroendocrine carcinomas, and into low-grade typical and intermediate grade atypical carcinoid. The only non-epithelial neuroendocrine tumor of the lung is pulmonary paraganglioma. In this short review, we will focus on the low and intermediate grade neuroendocrine tumors only. The review will touch on history, terminology, epidemiology, morphology, biology, and prognosis, and very briefly discuss therapeutic aspects. This review does not intend to completely discuss the vast amount of literature written on this subject, but will only cite the most relevant literature data.
Vorheriger Artikel Video-assisted thoracoscopic pneumonectomy: a minimally invasive approach for a rare inidication
Nächster Artikel The role of maintenance strategies in upper gastrointestinal (GI) and pancreatic carcinoma
Literatur
1.
Feyrter F. A morphologic principle of central and peripheral endocrine regulation. Klin Wochenschr. 1950;28:533–5.PubMedCrossRef
2.
Feyrter F. Argyrophilia of bright cell system in bronchial tree in man. Z Mikrosk Anat Forsch. 1954;61:73–81.PubMed
3.
Feyrter F. On the distinguishing features between bronchial carcinoid and bronchial muciparous adenoma. Frankf Z Pathol. 1959;69:659–66.PubMed
4.
Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA. Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg. 1985;89:819–25.PubMed
5.
Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Hum Pathol. 1998;29:272–9.PubMedCrossRef
6.
Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC WHO classification of tumours. Lyon: IARC Press; 2004.
7.
Gortz B, Roth J, Krahenmann A, de Krijger RR, Muletta-Feurer S, Rutimann K, Saremaslani P, Speel EJ, Heitz PU, Komminoth P. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol. 1999;154:429–36.PubMedCrossRef
8.
Petzmann S, Ullmann R, Halbwedl I, Popper HH. Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study. Virchows Arch 2004;445:151–9.PubMedCrossRef
9.
Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M, Travis WD. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol. 1996;148:1531–41.PubMed
10.
Onuki N, Wistuba II, Travis WD, Virmani AK, Yashima K, Brambilla E, Hasleton P, Gazdar AF. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 1999;85:600–7.PubMedCrossRef
11.
Klemen H S-JF, Popper HH. Morphological and Immunohistochemical study of typical and atypical carcinoids of the lung, on the bases of 55 cases with clinico-pathological correlation and proposal of a new classification. Endocrine-related Cancer. 1994;1:53–62.CrossRef
12.
Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–44.PubMedCrossRef
13.
Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005;29:179–87.PubMedCrossRef
14.
Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB, Nieman L, Chrousos G, Pass H, Doppman J. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–53.PubMedCrossRef
15.
Borges M, Linnoila RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M, Baylin SB, Ball DW. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997;386:852–5.PubMedCrossRef
16.
Walker C, Wright-Perkins S, Carbone DP, Koros AM, Linnoila RI, Jewett P, Gazdar AF, Komminoth P, Roth J, Lackie PM, Bitter-Suermann D, Heitz PU, Doyle LA, Borges M, Hussain A, Elias A, Tomiyasu T. Expression of neuroendocrine and epithelial markers in an adherent subline derived from a classic small cell lung cancer cell line. Oncol Res. 1992;4:419–29.PubMed
17.
Pusceddu S, Catena L, Valente M, Buzzoni R, Formisano B, Del Vecchio M, Ducceschi M, Tavecchio L, Fabbri A, Bajetta E. Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis. J Thorac Dis. 2010;2:16–20.PubMed
18.
Smolle-Juttner FM, Popper H, Klemen H, Pinter H, Pongratz-Roeger M, Smolle J, Friehs G. Clinical features and therapy of “typical” and “atypical” bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma). Eur J Cardiothorac Surg. 1993;7:121–4; (discussion 125).PubMedCrossRef
19.
Ullmann R, Schwendel A, Klemen H, Wolf G, Petersen I, Popper HH. Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization. Hum Pathol. 1998;29:1145–9.PubMedCrossRef
20.
Ullmann R, Petzmann S, Klemen H, Fraire AE, Hasleton P, Popper HH. The position of pulmonary carcinoids within the spectrum of neuroendocrine tumors of the lung and other tissues. Genes Chromosom Cancer. 2002;34:78–85.PubMedCrossRef
21.
Petzmann S, Ullmann R, Klemen H, Renner H, Popper HH. Loss of heterozygosity on chromosome arm 11q in lung carcinoids. Hum Pathol. 2001;32:333–8.PubMedCrossRef
22.
Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW, Goldstraw P. The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3:1213–23.PubMedCrossRef
23.
Vallieres E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:1049–59.PubMedCrossRef
24.
Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol. 2010;21:548–55.PubMedCrossRef
25.
Ono K, Suzuki T, Miki Y, Taniyama Y, Nakamura Y, Noda Y, Watanabe M, Sasano H. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res. 2007;27:2231–9.PubMed
26.
King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–61.CrossRef
27.
Zhou Q, Pardo A, Konigshoff M, Eickelberg O, Budinger GR, Thavarajah K, Gottardi CJ, Jones J, Varga J, Selman M, Sznajder JI, Raj JU, Zhou G. Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis. Faseb J. 2011;25:3032–44.PubMedCrossRef
28.
Aubertine CL, Flieder DB. Primary paraganglioma of the lung. Ann Diagn Pathol. 2004;8:237–41.PubMedCrossRef
29.
Shibahara J, Goto A, Niki T, Tanaka M, Nakajima J, Fukayama M. Primary pulmonary paraganglioma: report of a functioning case with immunohistochemical and ultrastructural study. Am J Surg Pathol. 2004;28:825–9.PubMedCrossRef
30.
Carney JA. Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocrinol Metab. 2009;94:3656–62.PubMedCrossRef
31.
Anderson RJ, Lynch HT. Familial risk for neuroendocrine tumors. Curr Opin Oncol. 1993;5:85–90.
Metadaten
Titel
The pathology of low and intermediate neuroendocrine lung tumors
verfasst von
Helmut H Popper, MD
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0047-7

Weitere Artikel der Ausgabe 1/2013

Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications

  • review

Treatment results for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries

  • editorial

Development of treatment and clinical results in childhood acute myeloid leukemia in Poland

  • Open Access
  • review

Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic

  • short review

Video-assisted thoracoscopic pneumonectomy: a minimally invasive approach for a rare inidication

  • case report

Future of stereotactic intervention in lung cancer

  • editorial